Anna E Wentz1, Ralph C Wang2, Brandon D L Marshall1, Theresa I Shireman3, Tao Liu4, Roland C Merchant5. 1. Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island. 2. Department of Emergency Medicine, University of California, San Francisco, San Francisco, California. 3. Brown University School of Public Health, Providence, Rhode Island. 4. Data and Statistics Core of Brown Alcohol Research Center on HIV (ARCH), Brown University School of Public Health, Providence, Rhode Island. 5. Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island; Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, Rhode Island; Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: Severe acute pain is still commonly treated with opioid analgesics in the United States, but this practice could prolong the duration of pain. OBJECTIVES: Estimate the risk of experiencing persistent pain after opioid analgesic use after emergency department (ED) discharge among patients with suspected urolithiasis. METHODS: We analyzed data collected for a longitudinal, multicenter clinical trial of ED patients with suspected urolithiasis. We constructed multilevel models to estimate the odds ratios (ORs) of reporting pain at 3, 7, 30, or 90 days after ED discharge, using multiple imputation to account for missing outcome data. We controlled for clinical, demographic, and institutional factors and used weighting to account for the propensity to be prescribed an opioid analgesic at ED discharge. RESULTS: Among 2413 adult ED patients with suspected urolithiasis, 62% reported persistent pain 3 days after discharge. Participants prescribed an opioid analgesic at discharge were OR 2.51 (95% confidence interval [CI] 1.82-3.46) more likely to report persistent pain than those without a prescription. Those who reported using opioid analgesics 3 days after discharge were OR 2.24 (95% CI 1.77-2.84) more likely to report pain at day 7 than those not using opioid analgesics at day 3, and those using opioid analgesics at day 30 had OR 3.25 (95% CI 1.96-5.40) greater odds of pain at day 90. CONCLUSIONS: Opioid analgesic prescription doubled the odds of persistent pain among ED patients with suspected urolithiasis. Limiting opioid analgesic prescribing at ED discharge for these patients might prevent persistent pain in addition to limiting access to these medications.
BACKGROUND: Severe acute pain is still commonly treated with opioid analgesics in the United States, but this practice could prolong the duration of pain. OBJECTIVES: Estimate the risk of experiencing persistent pain after opioid analgesic use after emergency department (ED) discharge among patients with suspected urolithiasis. METHODS: We analyzed data collected for a longitudinal, multicenter clinical trial of ED patients with suspected urolithiasis. We constructed multilevel models to estimate the odds ratios (ORs) of reporting pain at 3, 7, 30, or 90 days after ED discharge, using multiple imputation to account for missing outcome data. We controlled for clinical, demographic, and institutional factors and used weighting to account for the propensity to be prescribed an opioid analgesic at ED discharge. RESULTS: Among 2413 adult ED patients with suspected urolithiasis, 62% reported persistent pain 3 days after discharge. Participants prescribed an opioid analgesic at discharge were OR 2.51 (95% confidence interval [CI] 1.82-3.46) more likely to report persistent pain than those without a prescription. Those who reported using opioid analgesics 3 days after discharge were OR 2.24 (95% CI 1.77-2.84) more likely to report pain at day 7 than those not using opioid analgesics at day 3, and those using opioid analgesics at day 30 had OR 3.25 (95% CI 1.96-5.40) greater odds of pain at day 90. CONCLUSIONS: Opioid analgesic prescription doubled the odds of persistent pain among ED patients with suspected urolithiasis. Limiting opioid analgesic prescribing at ED discharge for these patients might prevent persistent pain in addition to limiting access to these medications.
Authors: Dean Assimos; Amy Krambeck; Nicole L Miller; Manoj Monga; M Hassan Murad; Caleb P Nelson; Kenneth T Pace; Vernon M Pais; Margaret S Pearle; Glenn M Preminger; Hassan Razvi; Ojas Shah; Brian R Matlaga Journal: J Urol Date: 2016-05-27 Impact factor: 7.450
Authors: Basmah Safdar; Linda C Degutis; Keala Landry; Swarupa R Vedere; Harry C Moscovitz; Gail D'Onofrio Journal: Ann Emerg Med Date: 2006-08 Impact factor: 5.721
Authors: Polly Bijur; Anick Bérard; Jordan Nestor; Yvette Calderon; Michelle Davitt; E John Gallagher Journal: Am J Emerg Med Date: 2008-03 Impact factor: 2.469
Authors: Sameer A Pathan; Biswadev Mitra; Lahn D Straney; Muhammad Shuaib Afzal; Shahzad Anjum; Dharmesh Shukla; Kostantinos Morley; Shatha A Al Hilli; Khalid Al Rumaihi; Stephen H Thomas; Peter A Cameron Journal: Lancet Date: 2016-03-16 Impact factor: 79.321